A phase II trial and quality-of-life analysis of a 5-day regimen of oral 5-fluorouracil bracketed by a 7-day regimen of oral eniluracil in untreated patients with unresectable or metastatic colorectal carcinoma
TimothyJ. Hobday , MichelleR. Mahoney , DanielJ. Sargent , JeffA. Sloan
Clinical Therapeutics 24 47 -48
1
2002
Biomarkers, subgroup evaluation, and clinical trial design.
Stuart G. Baker , Barnett S. Kramer , Marco Bonetti , Daniel J. Sargent
Discovery Medicine 13 ( 70) 187 -192
28
2012
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Howard McLeod , Daniel J. Sargent , Richard M. Goldberg
Transactions of the American Clinical and Climatological Association 121 21
1
2010
The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer
Charles Erlichman , Daniel J. Sargent , Richard M. Goldberg
Humana Press, Totowa, NJ 191 -198
2003
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine
Sumithra J. Mandrekar , Daniel J. Sargent
Chinese clinical oncology 3 ( 2) 14 -14
8
2014
Phase III Evaluation of Octreotide versus Chemotherapy with 5-Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study
Steven A. Kuross , James A. Mailliard , John C. Michalak , Patrick A. Burch
Clinical Cancer Research 6 ( 9) 3486 -3492
27
2000
Introduction to special issue on biomarker-based clinical trial designs in oncology
Sumithra J Mandrekar , Daniel J. Sargent , Axel F Grothey
Chinese clinical oncology 4 ( 3) 28 -28
2015
Statistical issues in tumor marker studies.
Lisa M. McShane , M. Elizabeth H. Hammond , Daniel J. Sargent , Thomas F. Pajak
Archives of Pathology & Laboratory Medicine 124 ( 7) 1011 -1015
32
2000
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
Lindsay A. Renfro , Daniel J. Sargent , Christina M. Coughlin , Axel M. Grothey
Chinese clinical oncology 3 ( 1) 3 -3
12
2014
Key statistical concepts in cancer research.
Qian Shi , Daniel J. Sargent
Clinical advances in hematology & oncology 13 ( 3) 180 -185
1
2015
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
Lawrence J. Burgart , Carolyn C. Compton , Christopher Willett , Mary L. Nielsen
Archives of Pathology & Laboratory Medicine 124 ( 7) 979 -994
1,609
2000
Mining the ACCENT database: a review and update
Lindsay A. Renfro , Daniel J. Sargent , Qian D Shi
Chinese clinical oncology 2 ( 2) 18 -18
6
2013
Overview: biostatistician's role in oncology clinical trials-strive for sound, efficient and practical studies.
Daniel J. Sargent , Qian D Shi
Chinese clinical oncology 3 ( 1) 1 -1
6
2014
Novel endpoints in phase III clinical trials.
Daniel J. Sargent
Clinical advances in hematology & oncology 3 ( 1) 21 -23
2
2005
Advances in defective mismatch repair colon cancer.
Daniel J. Sargent
Clinical advances in hematology & oncology 6 ( 9) 639 -641
1
2008
Biostatistics and bioinformatics
Daniel J. Sargent , Qian D Shi
Wolters Kluwer Health Adis (ESP) 290 -300
2012
Is disease-free survival an appropriate primary end point for adjuvant colon cancer studies?
Sharlene Gill , Daniel J. Sargent
American Journal of Oncology Review 5 ( 6) 370 -372
2006
Statistical methods frequently used in cancer research
Ayalew Tefferi , Daniel J. Sargent , Georgene Schroeder
Cancer Research Therapy and Control 9 333 -343
1999
Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database.
Mohamed E. Salem , Jun Yin , Lindsay A. Renfro , Benjamin Adam Weinberg
Journal of Clinical Oncology 35 675 -675
3
2017
Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database.
Alexis Diane Leal , Fang-Shu Ou , Aimery De Gramont , Levi Pederson
Journal of Clinical Oncology 35 757 -757
2017